Ophthalmic Suspension Market Research Report - Global Forecast Till 2027

Ophthalmic Suspension Market Information: By Type of Content (Antibiotic, Antifungal, Antibacterial, Steroids, Nsaids and others), By Applications (Bacterial Infections, Retinal Disorders, Glaucoma, Allergies, Diabetic Eye Disease), By End Users (Hospitals, Eye Clinics, Pharmacies, and others) - Global Forecast till 2027

ID: MRFR/MED/2964-HCR | February 2021 | Region: Global | 110 pages

Ophthalmic Suspension Market Scenario

The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a combination of two such as antibiotics and a corticosteroid for more effective treatment. Various bacterial eye infections such as conjunctivitis are treated by ophthalmic suspension.   


Increasing prevalence of eye diseases across the globe is one of the major factors contributing to the growth of this market. Moreover, increasing geriatric population which are most prone to eye disorders, and growing number of bacterial infections cases in children will also boost the growth of the market. Furthermore, according to WHO (2014), glaucoma is the second major cause of blindness in the world which will increase the market growth.


On the other hand, the side-effects of ophthalmic suspension may hamper the market growth during the corresponding period.


The global ophthalmic suspension market is expected to grow at a CAGR of ~6.8% during the forecast period 2017-2023.


FIGURE 1 Global Ophthalmic Suspension Market, by Application, 2016 (%) 
Ophthalmic Suspension Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders,

The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Segments            

The global ophthalmic suspension market is segmented on the basis of type of content, which is segmented into antibiotic, antifungal, antibacterial, steroids, NSAIDs (non-steroidal anti-inflammatory drugs) and others.


On the basis of applications, it is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease, and others. Bacterial infection is further conjunctivitis, scleritis, and others. Retinal disorder is further segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.   


On the basis of end user, the market is segmented into hospitals, eye clinics, pharmacies, and others.  

Key Players in the Global Ophthalmic Suspension Market                      

Some of the key players in this market are Novartis AG (Alcon), ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant,  Bayer AG, and Genentech, Inc.   


Research Methodology 
Global Ophthalmic Suspension Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Global Ophthalmic Suspension Market          

The American region accounted for the largest share of the global ophthalmic suspension market due to increasing prevalence of eye related diseases and increasing demand for new ophthalmic suspension for its treatment. Moreover, increasing geriatric population is another major factor responsible for the market growth in American countries.


Europe is the second largest ophthalmic suspension market across the globe owing to increasing awareness regarding eye related diseases, growing technological advancements in healthcare domain and increasing investment in healthcare domain by government.


In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of ophthalmic clinics, and increasing prevalence of eye related diseases drives the growth of the market in this region.


The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain.


The report on the global ophthalmic suspension market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions

Intended Audience



  • Ophthalmic Suspension Manufacturers

  • Ophthalmic Suspension Suppliers

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Frequently Asked Questions (FAQ) :


Ophthalmic suspension market can expand at 6.8% CAGR from 2017 to 2023.

High prevalence of eye diseases is the biggest driver of the global ophthalmic suspension market.

Adverse effects of ophthalmic suspension can impede the growth of the global ophthalmic suspension market.

The Americas can dominate the global ophthalmic suspension market till 2023 owing to high prevalence of eye diseases.

Genentech, Inc., Valeant, ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Bayer AG, and Novartis AG (Alcon) are notable players of the global ophthalmic suspension market.

Brief TOC

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain

5.3 Investment Feasibility Analysis

5.4 Price Factor Analysis

6 Global Ophthalmic Suspension Market, By Type of Content

6.1 Introduction

6.2 Antibiotic

6.3 Antifungal

6.4 Antibacterial

6.5 Steroids

6.6 NSAIDs

6.7 Others

7 Global Ophthalmic Suspension Market, By Application

7.1 Introduction

7.2 Bacterial Infections

7.3 Retinal Disorders

7.4 Glaucoma

7.5 Allergies

7.6 Diabetic Eye Disease

7.7 Others

8 Global Ophthalmic Suspension Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Eye Clinics

8.4 Pharmacies

8.5 Others

9 Global Ophthalmic Suspension Market, By Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 UK

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe
9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Republic of Korea

9.4.5 Australia

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 ALLERGAN

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Merck & Co., Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis AG (Alcon)

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bausch & Lomb Incorporated

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Falcon Group

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Pfizer Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Valeant

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Eye-Care Industry

13 Appendix